首頁 > 市場調查報告書 > 製藥 > 疫苗 > 淋巴癌、細胞死亡、癌症疫苗：藥劑開發策略分析

聯絡我們?

市場調查報告書

淋巴癌、細胞死亡、癌症疫苗：藥劑開發策略分析

Triple Analysis: Lymphoma, Apoptosis and Cancer Vaccines

出版商	BioSeeker Group AB
出版日期	2011年12月	商品編碼	195936
內容資訊	英文 3230 Pages
價格	US $ 5175 PDF by E-mail

簡介
目錄
相關商品

淋巴癌、細胞死亡、癌症疫苗：藥劑開發策略分析 是由出版商BioSeeker Group AB在2011年12月所出版的。這份英文市場調查報告書包含3230 Pages 價格從美金5175起跳。

簡介

本報告針對淋巴癌的藥物開發策略與細胞死亡及癌症疫苗的機制、目的、影響藥物開發策略為焦點，提供以臨床實驗治療藥物評價法為基礎的評估與藥物開發策略比較，目錄介紹如下。

第1章淋巴癌

本報告範圍
以最佳治療結果與投資回收率為前提的治療標的分析
新藥登場：開發階段分類淋巴癌藥物目標策略
使用中的複合策略：複合策略分類競爭基準
淋巴癌治療藥物適應症選擇
臨床實驗與分析計劃：淋巴臨床實驗競爭基準
免責事項
藥物索引
企業索引
圖表

第2章細胞死亡

本報告範圍
以最佳治療結果與投資回收率為前提的治療目標
新藥登場：癌症細胞死亡治療藥物管道的特定藥劑目標策略，是否有成熟的藥物目標策略、獨特性、有臨床評價
使用中的複合策略：化合物種類分類競合競爭基準
臨床實驗與分析計劃：細胞死亡競爭基準
藥物索引
企業索引
圖表

第3章癌症疫苗

本報告範圍
以最佳治療結果與投資回收率為前提的治療目標
新藥登場：開發階段分類癌症疫苗藥物目的策略
使用中的複合策略：複合策略分類競爭基準
藥物影響與癌症疫苗的癌症適應症：癌症疫苗競爭基準
臨床實驗與分析計劃
免責事項
藥物索引
企業索引

This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

KEY TOPICS COVERED:

Part I: Lymphoma

5.1. The Scope of this Report
6. Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets)
7. Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs)
8. Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies)
9. Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma)
10. Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies)
11. Disclaimer
12. Drug Index
13. Company Index

Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part II: Apoptosis

5.1. The Scope of this Report
6. Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (146 Drug Targets)
7. The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Apoptotic Therapeutic Pipeline? (120 Drug Target Strategies and 171 Drugs)
8. Compound Strategies at Work: Competitive Benchmarking of Apoptotic Drugs in Oncology by Compound Type (7 Different Compound Strategies)
9. Selecting Cancer Indications for Apoptotic Therapeutics (53 Cancer Indications)
10. Portfolio Planning: Competitive Benchmarking of Apoptotic Cancer Therapeutic Pipeline by Investigator (125 Investigators)
12. Drug Index
13. Company Index

Figures: Includes 6 Figures
Tables: Includes 248 Tables
Total Number of Pages: 803

Part III: Cancer Vaccines

5.1. The Scope of this Report
6. Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (94 Drug Targets)
7. Emerging New Products to Established Ones: Drug Target Strategies of Cancer Vaccine Drugs by their Highest Stage of Development (91 Drug Target Strategies and 155 Cancer Vaccine Drugs)
8. Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies)
9. Selecting Cancer Indications for Cancer Vaccine Drugs (42 Cancer Indications)
10. Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Investigator (99 Investigators)
11. Disclaimer
12. Drug Index
13. Company Index

Figures: Includes 6 Figures
Tables: Includes 205 Tables
Total Number of Pages: 659

FEATURED COMPANIES:

This Report Includes the Following Companies:

4SC
Abbott
Abiogen
AC Immune
Access
Adaptimmune
Aduro BioTech
Advanced Life Sciences
Advaxis
AEgera
AEterna Zentaris
Affimed Therapeutics
Agenus
Aida Pharmaceuticals
Akela Pharma
Alfa Wassermann
Alfacell
Allos Therapeutics
AlphaVax
Ambit Biosciences
Ambrilia Biopharma
Amgen
Anavex Life Sciences
Antisoma
Aphios
ApopLogic Pharmaceuticals
Apricus Biosciences
Apthera
Ariad
Arno Therapeutics
ArQule
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
Benitec
BioAxone
Biocon
BioCryst Pharmaceuticals
Biogen Idec
BioInvent
Biolex
Bionovo
Biostar
BioVex
Boehringer Ingelheim
Borean Pharma
Bristol-Myers Squibb
BTG
Cadila
Cancer Research Technology
Celera
Celgene
Cell Genesys
Cell Therapeutics
Celldex Therapeutics
Celltrion
Cephalon
CG Therapeutics
ChemoCentryx
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CSL
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytochroma
Cytokinetics
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Dendreon
DeveloGen
Dr Reddy' s
Dynavax Technologies
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Exelixis
Favrille
Forma Therapeutics
Gemin X Biotechnologies
Genencor
Genentech
Generex
Genmab
GenOdyssee Pharmaceuticals
GenPat77
Genta
GENTICEL
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlobeImmune
GlycoGenesys
Gradalis
Hayashibara
Heber Biotec
HemaQuest
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Ichor Medical Systems
Idera Pharmaceuticals
IGF Oncology
ImmunoCellular Therapeutics
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Inex
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Inovio
Insmed
Intas Biopharmaceuticals
Intracel
Intradigm
Introgen Therapeutics
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Italfarmaco
Johnson & Johnson
Kalypsys
Kinex
Kissei
Kyowa Hakko Kirin
Leo
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
Meda
Medical Marketing International
MediGene
MedImmune
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
MethylGene
Micromet
MolMed
Mologen
Nektar Therapeutics
Nemod Biotherapeutics
NeoPharm
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
NIH
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novartis
NovaRx
Novelix
Novogen
Noxxon
Nycomed Pharma
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Onyvax
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
OXiGENE
PanaGin
Pepscan Systems
Pepscan Therapeutics
Pfizer
Pharmacyclics
PharmaMar
Pharmexa
Pharminox
Philogen
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
Prima Biomed
Progenics Pharmaceuticals
ProNAi Therapeutics
Protherics
Radient Pharmaceuticals
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
responsif
Rigel
Sanofi-Aventis
Santaris Pharma
SBIO
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Shire
Sigma-Tau
SRI International
SuperGen
SuppreMol
Switch Pharma
Symbiotec
Synageva BioPharma
Takeda
Tapestry Pharmaceuticals
TapImmune
Taxolog
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Tigris Pharmaceuticals
Titan Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Transgene
Trion Pharma
United Biomedical
Vaccinex
Vascular Biogenics
Vaxil BioTherapeutics
Vaxon Biotech
VaxOnco
Vectura
VentiRx Pharmaceuticals
Vertex Pharmaceuticals
Vical
Vion Pharmaceuticals
VioQuest
Viragen
Viralytics
Virionics
ViroMed
ViroTarg
XBiotech
Xencor
Yakult Honsha
Zenotech
Zensun
Zenyaku Kogyo
ZymoGenetics
A Shortlist of Drugs Included are:
131I-tositumomab
2-methoxyestradiol
ABT-263
ADXS11-001
AE-37
AEG-35156
afutuzumab
alemtuzumab
ALVAC-CEA/B7.1
alvocidib
amrubicin hydrochloride
Apomab
ARQ-197
AS-1411
astuprotimut-r
atiprimod dimaleate
ATN-224
AVX-701
belagenpumatucel-L
belinostat
bexarotene
bortezomib
BP-GMAX-CD1
brentuximab vedotin
BZL-101
Cadi-05
canfosfamide hydrochloride
CB-10-01
CBLC-102
CEA-TRICOM
cenersen
CG-201
cintredekin besudotox
cladribine
CMLVAX-100
combretastatin A-4 prodrug
conatumumab
CS-1008
CTL901
CTP-37
CVac
DCVax-prostate
denileukin diftitox
dulanermin
E-75
elliptinium acetate
enzastaurin hydrochloride
epirubicin
everolimus
fowlpox-PSA vaccine
galiximab
GCS-100LE
GRN-163L
GRNVAC1
GV-1001
GV-1002
GVAX
GVX-3322
HBP-347
HE-3235
Her-2/Neu peptides
ibritumomab tiuxetan
idronoxil
IGN-101
ImmunoVEX tri-melan
IMO-2055
indisulam
INGN-225
INGN-241
INGN-401
inotuzumab ozogamicin
interferon (alpha)
interferon (alpha2b)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
irinotecan hydrochloride
ISIS-23722
kahalalide F
lonaprisan
lumiliximab
MAGE-3-TK
mapatumumab
ME-103
MGCD-0103
MGN-1601
mitoxantrone
MKC-1
motexafin gadolinium
MSI vaccine
MVA-BN
MVA-BN Her-2 vaccine
Norelin
obinutuzumab
oblimersen sodium
ofatumumab
Onyvax-105
OTS-102
panobinostat
PANVAC-VF
PARP inhibitors
PAT-SC1
patupilone
PCI-24781
pDOM-PSMA27
PEP-223
pixantrone
plitidepsin
poly-ICLC
PR1:169-177 peptide
pralatrexate
PROSTVAC
PX-104.1
quarfloxacin
razoxane
Reditux
retaspimycin
Reximmune-C
Rh-Apo2L
rhIFN-alpha
rindopepimut
rituximab
romidepsin
sagopilone
SAI-EGF
seliciclib
sobuzoxane
Stimuvax
temsirolimus
teniposide
TG-4001
TG-4010
thymalfasin
tigapotide triflutate
TLN-232
triciribine
TroVax
TRU-016
verpasep caltespen
voreloxin
VX-001
VX-944
XL-647
zanolimumab

ZYC-300

簡介
目錄
相關商品

使用指南產品及服務須知網站導覽

星期一到星期五 / 9:30am - 6:00pm
TEL: 02-2729-4219 (+886-2-2729-4219)
E-mail: tw-info@gii.co.jp

淋巴癌、細胞死亡、癌症疫苗：藥劑開發策略分析

Triple Analysis: Lymphoma, Apoptosis and Cancer Vaccines